Robert Dwyer Nolan
Directeur/Membre du Conseil chez Phico Therapeutics Ltd.
Profil
Robert Dwyer Nolan is the founder of Cardiff Biologicals Ltd.
He is currently a Non-Executive Director at Phico Therapeutics Ltd.
He was previously the Chairman of Cardiff Protides Ltd.
and held various Director positions at AstraZeneca PLC, Genedrive Plc, Epistem Ltd., NeuTec Pharma Ltd., and F2G Ltd.
He earned a doctorate degree from King's College London.
Postes actifs de Robert Dwyer Nolan
| Sociétés | Poste | Début |
|---|---|---|
Phico Therapeutics Ltd.
 Phico Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Phico Therapeutics Ltd. develops antibiotic bacteria resistant technology. Its products include SASPject PT1.2 used for intra-nasal decolonization, SASPject PT3.1 used for intra-abdominal infections and SASPject PT4 used for both the infections. The company was founded by Dr. Heather Fairhead and is headquartered in Cambridge, the United Kingdom. | Directeur/Membre du Conseil | - |
Anciens postes connus de Robert Dwyer Nolan
| Sociétés | Poste | Fin |
|---|---|---|
| GENEDRIVE PLC | Directeur/Membre du Conseil | 31/12/2018 |
Epistem Ltd.
 Epistem Ltd. BiotechnologyHealth Technology Epistem Ltd. engages in the provision of research solutions. It offers laser capture microdissection, imaging; microbiome, gene expression, NGS, DNA genotyping, and plucked hair analysis; Histology and IHC, and analytical services. The company was founded by Christopher Stanislaus Potten, Catherine Booth and Julie Tudor in 2000 and is headquartered in Manchester, the United Kingdom. | Directeur/Membre du Conseil | 01/10/2008 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01/01/2004 |
| Cardiff Biologicals Ltd. | Fondateur | - |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Directeur/Membre du Conseil | - |
Formation de Robert Dwyer Nolan
| King's College London | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| GENEDRIVE PLC | Health Technology |
| Entreprise privées | 6 |
|---|---|
Epistem Ltd.
Epistem Ltd. BiotechnologyHealth Technology Epistem Ltd. engages in the provision of research solutions. It offers laser capture microdissection, imaging; microbiome, gene expression, NGS, DNA genotyping, and plucked hair analysis; Histology and IHC, and analytical services. The company was founded by Christopher Stanislaus Potten, Catherine Booth and Julie Tudor in 2000 and is headquartered in Manchester, the United Kingdom. | Health Technology |
NeuTec Pharma Ltd.
 NeuTec Pharma Ltd. BiotechnologyHealth Technology NeuTec Pharma Ltd. develops biopharmaceutical products. It specializes in the development of genetically recombinant antibodies, or “grabs”, for the treatment of life-threatening infections. The firm's products include Mycograb and Aurograb. The company was founded in 1997 and is headquartered in Camberley, the United Kingdom. | Health Technology |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Health Technology |
| Cardiff Protides Ltd. | Commercial Services |
| Cardiff Biologicals Ltd. | Commercial Services |
Phico Therapeutics Ltd.
Phico Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Phico Therapeutics Ltd. develops antibiotic bacteria resistant technology. Its products include SASPject PT1.2 used for intra-nasal decolonization, SASPject PT3.1 used for intra-abdominal infections and SASPject PT4 used for both the infections. The company was founded by Dr. Heather Fairhead and is headquartered in Cambridge, the United Kingdom. | Commercial Services |